BridgeMD
New treatment option for ST Elevation Myocardial Infarction
Official title CRP Apheresis in STEMI
ClinicalTrials.gov ID: NCT04939805
What this study is testing
- What it's testing
- Background: In patients with acute ST-elevation myocardial infarction (STEMI), the amount of infarcted myocardium (infarct size) is known to be a major predictor for adverse remodeling and recurrent adverse cardiovascular events. Effective cardio-protective strategies with the aim of reducing infarct size are therefore of great interest.
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 85
You may be able to join if
- Diagnosis of first acute STEMI in accordance with the European Society of Cardiology (ESC) Guidelines for the management of acute myocardial...
- Symptoms consistent with STEMI with beginning greater than 30 minutes but less than 12 hours prior to primary percutaneous coronary intervention (PCI)
- CRP elevation of ≥7 mg/l measured between 6 to 16 hours after primary PCI
- Eligible for primary PCI
- Age ≥18 years
You likely can't join if
- Prior acute myocardial infarction, coronary artery bypass surgery or PCI.
- Persistent hemodynamic instability (Killip class \>2 including cardiogenic shock) or resuscitated cardiac arrest not allowing a CMR scan.
- The patient is febrile (temperature \>38°C) or has experienced an acute infection with fever in the last 14 days.
- CRP \>15 mg/l at time of hospital admission.
- Chronic inflammatory disease.
- Known history of severe hepatic failure
See the full eligibility criteria
- Diagnosis of first acute STEMI in accordance with the European Society of Cardiology (ESC) Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation
- Symptoms consistent with STEMI with beginning greater than 30 minutes but less than 12 hours prior to primary percutaneous coronary intervention (PCI)
- CRP elevation of ≥7 mg/l measured between 6 to 16 hours after primary PCI
- Eligible for primary PCI
- Age ≥18 years
- Written informed consent
- Prior acute myocardial infarction, coronary artery bypass surgery or PCI.
- Persistent hemodynamic instability (Killip class \>2 including cardiogenic shock) or resuscitated cardiac arrest not allowing a CMR scan.
- The patient is febrile (temperature \>38°C) or has experienced an acute infection with fever in the last 14 days.
- CRP \>15 mg/l at time of hospital admission.
- Chronic inflammatory disease.
- Known history of severe hepatic failure
- Chronic kidney disease with a creatinine clearance \<30ml/min./1.73m²
- Contraindication to CMR.
- Pre-STEMI life expectancy of \<1 year
- Participation in another treatment trial
- Limited possibility to join the follow-up examinations (e.g. patient lives abroad)
- Pregnancy
The study team makes the final eligibility decision.
Where it's taking place
- Graz, Austria
- Innsbruck, Austria
- Salzburg, Austria
- Lübeck, Schleswig-Holstein, Germany
- Leipzig, Germany
Compensation & support
Compensation mentioned.
ClinicalTrials.gov doesn't provide a reliable structured field for payment or travel support - confirm details with the study team.
Questions & answers
Do participants get paid in this trial?
This study's listing includes signals that participants may be compensated or receive a stipend. Amounts vary and are set by the study team - confirm the details with them.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 85 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Graz, Austria; Innsbruck, Austria; Salzburg, Austria; Lübeck, Schleswig-Holstein, Germany; Leipzig, Germany. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.